Cited by 208Gastric Cancer Management and OutcomesCancer Immunotherapy and BiomarkersEsophageal Cancer Research and Treatment

The DOI matches its Crossref record.

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Open access

Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Poulart, V., Cullen, D., Lei, M., Kondo, K., Li, M., Ajani, J.A., Janjigian, Y.Y.·2020·Annals of Oncology

DOI 10.1016/j.annonc.2020.08.2296

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.08.2296

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 207

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study
Usón, P. L. S., Kunze, K. L., Golafshar, M. A., Botrus, G., Riegert‐Johnson, D. L., Boardman, L., Borad, M. J., Ahn, D. H., Sonbol, M. B., Kahn, A., et al. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07387-x · Cited by 13
Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial
Wei, J., Lu, X., Liu, Q., et al. (2022) · Cancer Management and Research · doi:10.2147/cmar.s355687 · Cited by 13
“1 months in chemotherapy alone cohort) by combining chemotherapy with anti-PD-(L)1.(15,16) As a result of this study, in April 2021 FDA approved nivolumab in combination with chemotherapy as the first-line treatment for advanced or metastatic G/GEJ and esophageal adenocarcinoma.”
Background
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature
de la Fouchardière, C., Decoster, L., Samalin, E., Terret, C., Kenis, C., Droz, J., Coutzac, C., & Smyth, E. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102289 · Cited by 13
Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma
Ignatova, E., Kozlov, E. M., Ivanov, M. V., Mileyko, V., Menshikova, S., Sun, H., Fedyanin, M. Y., Tryakin, A. A., & Stilidi, I. S. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i3.628 · Cited by 12
How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
Ghidini, M., Petrillo, A., Botticelli, A., Trapani, D., Parisi, A., Salvia, A. L., Sajjadi, E., Piciotti, R., Fusco, N., & Khakoo, S. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071412 · Cited by 12
“The Checkmate 649 trial (NCT02872116) randomized untreated metastatic GC patients to three arms: nivolumab plus ipilimumab, standard CT (Folfox or Xelox), standard CT plus nivolumab [98].”
BackgroundMethodInfluential
Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches
Lonie, J. M., Barbour, A. P., & Dolcetti, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102219 · Cited by 12
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer
Myer, N. M., Shitara, K., Chung, H. C., Lordick, F., Kelly, R. J., Szabó, Z. R., Cao, Z. A., Leong, S., Ilson, D. H., & Weichert, W. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03902-1 · Cited by 12
Self-citation
PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
Gou, M., Zhang, Y., Wang, Z., & Dai, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1136437 · Cited by 11
Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer
Smyth, E. C., & Cervantes, A. M. R. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001107 · Cited by 11
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy
Attia, H., & Smyth, E. C. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1866548 · Cited by 11
“who had tumors which expressed PD-L1 with a CPS score of 5 or greater [90].”
Background
Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal
Gervaso, L., Pellicori, S., Cella, C. A., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211029559 · Cited by 11
Management of Non-Colorectal Digestive Cancers with Microsatellite Instability
Zhu, M., Jin, Z., & Hubbard, J. M. (2021) · Cancers · doi:10.3390/cancers13040651 · Cited by 11
The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia
Nakamura, Y., Shitara, K., & Lee, J. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321247 · Cited by 11
Self-citation
Pathological Complete Response and Successful Conversion Surgery After Nivolumab Therapy for Stage IV Oesophagogastric Junction Cancer
Kumamoto, T., Tomita, T., Hojo, Y., et al. (2021) · In Vivo · doi:10.21873/invivo.12497 · Cited by 10
Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials
Zheng, J.-Q., Huang, B., Xiao, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.821626 · Cited by 10
“, 2020s2202020202020 (24) III First-line GEJC ChT 792 792”
Background
Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)
Baxter, M. A., Petty, R., Swinson, D., Hall, P. S., & O’Hanlon, S. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5202 · Cited by 10
“Again, grade 3+ toxicity was high at 59% in the combination arm (15).”
Background
A Phase 2 Trial Combining Pembrolizumab and Palliative Radiation Therapy in Gastroesophageal Cancer to Augment Abscopal Immune Responses
Chao, J., He, T.-F., D’Apuzzo, M., et al. (2021) · Advances in Radiation Oncology · doi:10.1016/j.adro.2021.100807 · Cited by 10
“However, the benefit for incorporation of anti-PD-1 therapy still appears better delineated if PD-L1 CPS assessment exceeds certain thresholds of expression such as ≥5 in the CheckMate 649 trial adding nivolumab or ≥10 in the KEYNOTE-590 trial adding pembrolizumab.(8,9) As such, there still remains a fair proportion o…”
BackgroundMethod
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
Schlintl, V., Huemer, F., Rinnerthaler, G., Melchardt, T., Winder, T., Reimann, P., Riedl, J., Amann, A., Eisterer, W., Romeder, F., et al. (2022) · BMC Cancer · doi:10.1186/s12885-021-09115-6 · Cited by 10
“First results of the CheckMate-649 study were presented at ESMO meeting 2020, which demonstrated a promising survival benefit with frontline combination of chemotherapy and nivolumab in patients with PD-L1 CPS ≥ 5 [28].”
Result
Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer
Gan, X., Tang, X., & Li, Z. (2023) · Biomolecules · doi:10.3390/biom13030528 · Cited by 10
Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world
Hao, W., Liu, W., Chang, R., Yang, M., Xin, K., Liu, J., Wang, Y., Ren, M., Xie, J., & Yang, Y. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05703-8 · Cited by 9
“In addition, based on the results of the CheckMate 649, the first-line trial showed that nivolumab, in combination with the chemotherapy group, also better prolonged OS and PFS in patients with a CPS of 5 (Moehler et al. 2020).”
Result
Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study
Dai, X., Ding, W., He, Y., Huang, S., Liu, Y., & Wu, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1227644 · Cited by 8
Updated Adjuvant Chemotherapy for Gastric Cancer
Takayama, T., & Tsuji, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216727 · Cited by 11
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
Wu, J., Zhou, C.-F., Han, Z., Zhang, H., Yan, J., Chen, J., Wang, C., Qin, Z., Mao, Y., Tang, X. T., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02051-4 · Cited by 7
Addition of Sintilimab to Nanoparticle Albumin-Bound Paclitaxel and S-1 as Adjuvant Therapy in Stage IIIC Gastric Cancer
Mei, Y., Shi, M., Zhu, Z., Yuan, H., Yan, C., Li, C., Feng, T., Yan, M., Zhang, J., & Zhu, Z. (2021) · Future Oncology · doi:10.2217/fon-2021-1020 · Cited by 7
Protein-bound polysaccharide K prolonged overall survival in gastric cancer patients from a non-Japanese Asian country who received gastrectomy and adjuvant chemotherapy
Wang, T.-Y., Chen, C., Huang, T.-H., et al. (2022) · Medicine · doi:10.1097/md.0000000000029632 · Cited by 7
“[3] The benefit of adding immunotherapy to chemotherapy to treat gastric cancer in a metastatic or adjuvant setting has recently been demonstrated in 2 phase III trials.[31,32] In addition, combining PSK with adjuvant chemotherapy for gastric cancer has the additional benefit of not causing additional side effects in…”
Background
Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?
Khalafi, S., Lockhart, A. C., Livingstone, A. S., & El-Rifai, W. M. (2020) · Cancers · doi:10.3390/cancers12113077 · Cited by 7
Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry
Watanabe, M., Kuwata, T., Setsuda, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83711-1 · Cited by 7
Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature
Kamposioras, K., Ntellas, P., Nikolaou, M., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab088 · Cited by 7
“Survival outcomes were analyzed in intention-to-treat (ITT) method [16].”
BackgroundInfluential
Successes and failures of immunotherapy for gastric cancer
Wang, J., Tu, S., Chavda, V. P., Chen, Z., & Chen, X. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103343 · Cited by 7
Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma
Wang, Y., Zhao, J., Yu, H., et al. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_856_21 · Cited by 7
Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: A case report
Zhou, M., Xu, R.-N., Tan, C., et al. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i6.1096 · Cited by 6
Case report: Significant response of alpha-fetoprotein-producing gastric cancer from combined chemotherapy and immunotherapy
Da, X., Zhang, J., Hu, Z., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448875 · Cited by 6
Recent insights into the use of immune checkpoint inhibitors in gastric cancer
Rodrigues, S., & Figueiredo, C. (2022) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000162 · Cited by 6
“In particular, in patients with tumors expressing PD-L1 with CPS ≥5, nivolumab plus chemotherapy showed statistically significant improvements in both OS and PFS in comparison with chemotherapy alone.(32) Based on the results of the CHECKMATE-649 trial, the European Medicines Agency validated(40) and the US FDA accept…”
Result
A Novel DNA Repair Gene Signature for Immune Checkpoint Inhibitor-Based Therapy in Gastric Cancer
Yuan, B., Jiang, C., Chen, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.893546 · Cited by 6
Brazilian Group of Gastrointestinal Tumours’ consensus guidelines for the management of oesophageal cancer
Rocha-Filho, D. R., Peixoto, R. D., Weschenfelder, R. F., et al. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1195 · Cited by 6
Targeted therapy in esophageal cancer
Hassan, S., Makuru, V., & von Holzen, U. W. (2021) · Digestive Medicine Research · doi:10.21037/dmr-21-16 · Cited by 6
“In addition, there was also a statistically significant OS benefit in patients with PDL1 CPS ≥1, as well as the all-randomized population (40).”
Background
2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer
Kang, X., Qin, J., Zhang, R., Wang, Z., Zheng, Q., Li, Y., Xu, J., Huang, J. L., Wang, X., Hui, Z., et al. (2021) · Annals of Esophagus · doi:10.21037/aoe-21-64 · Cited by 6
“Immunotherapy trials for metastatic esophageal cancer, including the KEYNOTE-590 (6), CheckMate 649 (7), ATTRACTION-4 (8), KEYNOTE-181 (31), ATTRACTION-3 (32), and ESCORT (33) trials, show that”
BackgroundMethod
Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report
Liu, M., Luo, C., Xie, Z.-Z., et al. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i16.5420 · Cited by 6
Immune evasion strategies in AFP-producing gastric carcinoma: characterized by HLA-G expression and HLA class I deficiency
Yamazawa, S., Fukasawa-Hokazono, M., Takase, A., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04108-3 · Cited by 5
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
Gürler, F., Güven, D. C., Aydemir, E., et al. (2022) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5496 · Cited by 5
Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing trials
Lu, M., Wu, Y., Zhang, Y., Yu, Y., Wang, S., & Su, X. (2023) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-023-00192-1 · Cited by 5
“Therefore, the nivolumab combination therapy has been approved by FDA for the patients with advanced or metastatic GC [46].”
Background
Prädiktive Diagnostik für Checkpoint-Inhibitoren
Schildhaus, H., & Weichert, W. (2021) · Der Pathologe · doi:10.1007/s00292-021-00939-4 · Cited by 5
“Nach aktueller Datenlage ist zurzeit wohl am ehesten mit einer Nivolumab-/Chemotherapie-Zulassung beieinemCPSvon≥5zurechnen.”
BackgroundInfluential
Harnessing Biomarkers of Response to Improve Therapy Selection in Esophago-Gastric Adenocarcinoma
Fong, C., & Chau, I. (2021) · Pharmacogenomics · doi:10.2217/pgs-2020-0090 · Cited by 4
Neoadjuvante und perioperative Therapie des Magenkarzinoms, aktuelle Studien und neue Biomarker
Stocker, G., Thieme, R., & Lordick, F. (2021) · Der Chirurg · doi:10.1007/s00104-021-01355-3 · Cited by 4
“Aus der metastasierten Situation lassen sich Therapieeffekte für Immuncheckpointinhibitoren insbesondere bei PDL1-Expression und MSI ableiten [21].”
Background
Immunotherapy in Gastrointestinal Malignancies
Surana, R., & Pant, S. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_8 · Cited by 4
Immunotherapy use in oesophagogastric cancers—a review of the literature
Smith, A., Roy, A. C., Karapetis, C. S., Broadbridge, V. T., & Price, T. J. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01751-4 · Cited by 3
Pembrolizumab–chemotherapy for advanced oesophageal cancer
Gil, Z., & Billan, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01607-x · Cited by 4
Comparing immunotherapies to other frequently used treatments of gastric cancer
Basile, D., Simionato, F., Calvetti, L., Cappetta, A., Pesavento, A., Mongillo, M., Roviello, G., Rosati, G., Rossi, G., & Aprile, G. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1938546 · Cited by 3
Reduction of Cancer-Induced Thrombocytosis as a Biomarker of Improved Outcomes in Advanced Gastric Cancer
Konopka, K. W., Frączek, P. A., Lubaś, M. T., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051213 · Cited by 3
“or second-line therapies in this indication [31].”
Pathologic complete response to chemoimmunotherapy of an advanced gastric cancer patient with high PD-L1 expression, dMMR, and unique gut microbiota composition: A case report
Jiang, H., Wang, J., & Deng, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1150931 · Cited by 3
Magenkarzinom
Racz, K., Légner, A., Böhme, F., et al. (2023) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-023-01011-x · Cited by 3
Changes in the therapeutic landscape of oesophago-gastric cancers
Dovnik, N. F., & Smyth, E. C. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000728 · Cited by 3
Does immunotherapy change the treatment paradigm in metastatic gastric cancer?
Camera, S., Liscia, N., Foti, S., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01819-4 · Cited by 3
“More recently, the results of the global phase III CheckMate 649 trial were presented [24, 25] (Table 1).”
BackgroundMethod
The Rapidly Evolving Landscape of Advanced Gastric Cancer Therapy
Costa, G., Younes, H., Kourié, H. R., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1499 · Cited by 3
Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study
Mazzoli, G., Nichetti, F., Shitara, K., Cohen, R., Lonardi, S., Cremolini, C., Elez, M. E., Chao, J., Fakih, M., Klempner, S. J., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100037 · Cited by 2
Self-citation
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies
Maron, S. B., Xu, R., Wainberg, Z. A., Rha, S. Y., Zhang, Y., Pietrantonio, F., Oliveira, S. C. S., Li, Y., Chen, M.-H., Korphaisarn, K., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.107698 · Cited by 4
Self-citation
Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma
Jin, X. S., Wu, S., & Bai, Y. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06557-3 · Cited by 2
Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses
Mylod, E., McKenna, E., Davern, M., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00811-6 · Cited by 2
“With the recent approval of immune checkpoint inhibitor nivolumab plus chemotherapy as a first line treatment for advanced gastric cancer, it is evident that immunotherapies are beginning to make an impact in this space [2].”
Background
Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors
Ma, S., & Chen, F. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154110 · Cited by 2
Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?
Ng, M. C. H., & Choo, S. P. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4699 · Cited by 2
“The recent presented Phase III data of the KN-062, Checkmate 649 (CM-649) (27) and ATTRACTION-4 (ATT-4) (28) studies shed some light on this issue.”
BackgroundInfluential
Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study
Liu, Y., You, Y., Chen, L., Li, J., Yuan, M., Duan, B., Ge, H., Chen, X., Yang, L., Chen, X., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11904-7 · Cited by 2
“However, treatment response varies signi ﬁ cantly among individuals [5 – 7].”
Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
Deleporte, A., den Eynde, M. V., Forget, F., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3976 · Cited by 1
“Febrile neutropenia 9 (17) (9– 30) 4 (8) (3%– 19%)”
Immunotherapy for Gastroesophageal Tumors: Is there still Hope for Efficacy?
Ilhan‐Mutlu, A., & Puhr, H. C. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220117101105 · Cited by 1
Immunotherapy for the Treatment of Gastric Cancer with High Microsatellite Instability
Lee, S.-Y. (2022) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2022.10.2.117 · Cited by 1
Colony-stimulating factor 3 and its receptor promote leukocyte immunoglobulin-like receptor B2 expression and ligands in gastric cancer
Wang, L., Wu, Q., Zhang, Z.-W., et al. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.97858 · Cited by 1
Trifluridine/tipiracil plus ramucirumab in gastric cancer
Zhu, M., Sonbol, M. B., & Yoon, H. H. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00013-3 · Cited by 1
Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer
Mamdani, H. M., & Jalal, S. I. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321243 · Cited by 2
Adjuvant nivolumab for the management of pathological residual disease in esophageal or junctional tumors: a word of caution
Garg, P. K., Kumar, R., & Dixit, P. H. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.024 · Cited by 1
Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the Young International Society of Geriatric Oncology
Baxter, M. A., Marinho, J. C. L., Soto‐Pérez‐de‐Celis, E., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.09.006 · Cited by 1
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
Smyth, E. C., Cozens, K., Griffiths, D. E., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09891-9 · Cited by 1
“Finally, in the CheckMate 649 trial, adding nivolumab to chemotherapy did extend overall survival, but only for patients with high PD-L1 expression (CPS 5) [9].”
Method
Diagnostic Applications of Nuclear Medicine: Gastric Cancers
Sakellis, C. G., Jacene, H. A., & den Abbeele, A. D. V. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_14 · Cited by 1
Que retenir de l’année 2020 ?
Bay, J., André, T., Bouleuc, C., Gandemer, V., Magné, N., Orbach, D. H., Pellier, I., Penel, N., Rodrigues, M. J., Thariat, J., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.12.002
ESMO20 YO for YO: highlights on upper GI tumours
Cardone, C., Pihlak, R., & Smyth, E. C. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100023
Therapie von Tumoren des Magens und des Ösophagus - aktueller Stand
Masetti, M., & Lorenzen, S. (2021) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-021-8575-0
Onkologische Therapieprinzipien beim Magenkarzinom
Pluschnig, U. (2021) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-021-00093-x
Immuntherapie von Tumoren im oberen Gastrointestinaltrakt
Lorenzen, S., & Masetti, M. (2021) · Die Gastroenterologie · doi:10.1007/s11377-021-00533-3
Prädiktive Biomarker in der immunonkologischen Therapie gastrointestinaler Tumoren: derzeitiger Standard und zukünftige Perspektiven
Schwab, C., Glade, J., Budczies, J., Kluck, K., Kloor, M., & Stenzinger, A. (2021) · Die Gastroenterologie · doi:10.1007/s11377-021-00531-5
Interdisziplinäre Therapiekonzepte beim Ösophaguskarzinom
Pluschnig, U., & Zacherl, J. (2021) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-021-00099-5
Current state of chemotherapy and immunotherapy regimens in gastric cancer
Balasubramanian, A., John, A., & Segelov, E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85563-1.00008-3
Systems biology and molecular characterization of subtypes to guide targeted therapies in gastric cancer
Dings, M. P. G., Vermeulen, L., & Bijlsma, M. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85563-1.00001-0
Case studies highlighting the multiple facets of gastric cancer: one diagnosis, multiple approaches
Lum, C., & Frentzas, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85563-1.00010-1
Diagnostik und Therapie des Magenkarzinoms und Adenokarzinoms des ösophagogastralen Übergangs
Stocker, G., Bläker, H., Denecke, T., et al. (2021) · Der Onkologe · doi:10.1007/s00761-021-01029-z
Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies
Arrazubi, V., & Alsina, M. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_3
Stomach: The Standard of Care ± HER2
Moy, R. H., & Janjigian, Y. Y. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_4
Self-citation
Perspective on the Immunotherapy of Gastric Cancer
Kubota, Y., Kawazoe, A., & Shitara, K. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_5
Self-citation
Biomarkers for Immunotherapy in Gastrointestinal Cancers
Palle, J., Taı̈eb, J., & Zaanan, A. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_10
Diagnostik und Therapie des Magenkarzinoms und Adenokarzinoms des ösophagogastralen Übergangs
Stocker, G., Bläker, H., Denecke, T., et al. (2022) · Die Gastroenterologie · doi:10.1007/s11377-022-00598-8
Comparative efficacy and tolerability of target agents and immune checkpoint inhibitors in combination with chemotherapy as First-line treatment for advanced gastric cancer: A Bayesian network meta-analysisPreprint
Liu, S., Wong, H. Y., Xie, L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1557463/v1
Cáncer esofagogástrico en la era de inmunoterapia y terapias blanco
Ramos, P. L. (2022) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.397
Advances in immunotherapy for metastatic esophageal cancer
Darling, H. (2022) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_14_2022
Diagnostic Applications of Nuclear Medicine: Gastric Cancers
Sakellis, C. G., Jacene, H. A., & den Abbeele, A. D. V. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_14-2
Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer
Park, R., Abushalha, K., & Saeed, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_174-1
Immunotherapy in Gastrointestinal Malignancies
Uğraklı, M., Karaağaç, M., & Artaç, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_218-1
Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)
van den Ende, T., de Clercq, N. C., Henegouwen, M. I. V. B., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., et al. (2023) · doi:10.1158/1078-0432.c.6530261.v1
Data from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Peng, Z. J., Jia, W. P., Wang, F., Ying, J., Deng, Y., Gu, K., Cheng, Y., Yuan, X., Xiao, J., Tai, Y., et al. (2023) · doi:10.1158/1078-0432.c.6530120.v1
Self-citation
Long-term therapeutic response to treatment with nivolumab and chemotherapy in patients with adenocarcinoma of the stomach and gastro-oesophageal junction
Grell, P. (2023) · Klinická farmakologie a farmacie · doi:10.36290/far.2023.023
Immunotherapy for Gastrointestinal Malignancies
Uğraklı, M., Karaağaç, M., & Artaç, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_218-2
Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer
Park, R., Abushalha, K., & Saeed, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_174
Immunotherapy for Gastrointestinal Malignancies
Uğraklı, M., Karaağaç, M., & Artaç, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_218
Additional file 3 of ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
Smyth, E., Cozens, K., Griffiths, D., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20787085

Authors: Moehler, M., Shitara, K., Garrido, M., Salman, P., Shen, L., Wyrwicz, L., Yamaguchi, K., Skoczylas, T., Campos Bragagnoli, A., Liu, T., Schenker, M., Yanez, P., Tehfe, M., Poulart, V., Cullen, D., Lei, M., Kondo, K., Li, M., Ajani, J. A., & Janjigian, Y. Y.
Affiliations: University Medical Center of the Johannes Gutenberg University Mainz (DE)
National Cancer Center Hospital East (JP)
Fundación Arturo López Pérez (CL)
Peking University Cancer Hospital (CN)
The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
The Cancer Institute Hospital (JP)
Medical University of Lublin (PL)
Fudan University (CN)
Universidad de La Frontera (CL)
Centre Hospitalier de l’Université de Montréal (CA)
Bristol-Myers Squibb (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
Memorial Sloan Kettering Cancer Center (US)
ORCID: Shitara, K.
Salman, P.
Shen, L.
Wyrwicz, L.
Yamaguchi, K.
Skoczylas, T.
Schenker, M.
Yanez, P.
Tehfe, M.
Lei, M.
Kondo, K.
Ajani, J.A.
Janjigian, Y.Y.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2020-09
Volume: 31
Pages: S1191
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/j.annonc.2020.08.2296
OpenAlex: W3088611248
Cited by: 208
References: 0
Citations by year: 2026: 5 · 2025: 6 · 2024: 7 · 2023: 19 · 2022: 53 · 2021: 107 · 2020: 11
FWCI: 26.78
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Annals of Oncology (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
Keywords: nivolumab, PD-1 inhibitors, advanced gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, first-line chemotherapy, PD-L1 combined positive score, overall survival, progression-free survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks